This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 MT
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP CI
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating MT
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences CI
Sector Update: Health Care Stocks Slide Late Afternoon MT
Top Midday Gainers MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures MT
Top Premarket Gainers MT
Gilead Sciences Files a Definitive Proxy Statement CI
Gilead Sciences Files a Definitive Proxy Statement CI
Gilead Sciences Files a Definitive Proxy Statement CI
Gilead Sciences Inc Receives a Shareholder Proposal from David Bahnsen CI
Gilead Sciences Inc Receives a Shareholder Proposal from John Chevedden CI
Gilead Sciences Inc Receives a Shareholder Proposal from Jing Zhao CI
Xilio Shares Take Flight Premarket After Gilead Deal DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall MT
Gilead Says FDA Approves New Drug Application for Potential Hep-B Treatment for Smaller Children MT
Gilead Says FDA Expands Approval of Chronic Hep-B Infection Treatment for Use in Kids DJ
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12 MT
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six CI
Xilio Therapeutics Plans Private Placement, Job Cuts DJ
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program DJ
Xilio Therapeutics, Inc. announced that it expects to receive $11.3 million in funding CI
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.07 USD
Average target price
86.26 USD
Spread / Average Target
+26.72%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Gilead Eyes Expanded Liver Treatment Portfolio With $4.3 Billion Buyout of CymaBay Therapeutics